Anabolic androgenic steroid
DHB / 1-Testosterone
DHB, also called 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one), is listed among US Schedule III anabolic steroids.1 The figures shown are the app’s; no paper read reports a half-life, dose or time to peak.
DHB / 1-Testosterone after one dose: 50% at ~6 days, 25% at 12 days, 12.5% at 18 days.
Drawn from the half-life in the app's model, ~6 days. The model's figures
- Compound
- DHB / 1-Testosterone
- Symbol
- DHB
- Family
- Other steroids
- Parts
- 14
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
The app lists DHB as the abbreviation for dihydroboldenone, also called 1-testosterone. United States federal regulations list the structure 17β-hydroxy-5α-androst-1-en-3-one as “Δ1-dihydrotestosterone (a.k.a. “1-testosterone”)” among the Schedule III anabolic steroids.1 Fuchs and colleagues at Maastricht University, in Medicine and Science in Sports and Exercise in 2026, list “dihydroboldenone (1-testosterone)” in a table of drugs self-reported by 15 competitive bodybuilders who used appearance- and performance-enhancing drugs (APED).2 The app’s notes describe it as the 5-alpha reduced derivative of boldenone. The figures shown at the top (half-life, bioavailability, typical dose, route and time to peak) are the app’s own, and none of them is reported in the papers read.
A search of PubMed on 16 November 2026 for the single term dihydroboldenone in any field returned 1 record, a 1999 paper on a mass spectrometry method for anabolic steroids in human urine, whose summary lists “4-dihydroboldenone” and does not say whether that is 1-testosterone.3 A search of PubMed for “1-testosterone” in the title returned 17 records on the same date, and none of the 17 titles describes giving 1-testosterone to people to measure its levels or effects. Searches of ClinicalTrials.gov and of DailyMed drug labels used that same single term, dihydroboldenone, and returned 0 studies and 0 labels; neither was run for “1-testosterone”, “DHB” or “Δ1-dihydrotestosterone”. The papers and documents read are laboratory and animal work, product analysis, anti-doping chemistry and regulatory listings, and several of the papers involve people in some way: a volunteer who took a related supplement, a cross-sectional imaging study of bodybuilders, a case report on a different compound, and urine methods or metabolite work in people.
How it works
Sources in this part
In molecular experiments, Friedel and colleagues at the German Sport University Cologne (Toxicology Letters, 2006) reported that 1-testosterone “binds highly selective to the androgen receptor (AR) and has a high potency to stimulate AR dependent transactivation”.4 In vivo, they report that “an equimolar dose of 1-Testo has the same potency to stimulate the growth of the prostate, the seminal vesicles and the androgen sensitive levator ani muscle as the reference compound testosterone propionate (TP)”.4 They add that administration of 1-testosterone, “in contrast to TP, results in a significant increase of liver weight”.4 The authors conclude that 1-testosterone, “even without being metabolised, is a very potent androgen”.4 The app’s notes state that it does not undergo aromatization, and a search of PubMed on 16 November 2026 for 1-testosterone with aromatase or aromatization terms returned 5 records, none of whose titles concerns aromatization of 1-testosterone.
Deeper analysis: Friedel and colleagues, 2006
Friedel and colleagues, whose record lists one affiliation for the nine authors, the Center for Preventive Doping Research at the German Sport University Cologne, state that they “characterised molecular mechanisms of its action, determined its tissue specific androgenic and anabolic potency and investigated potential adverse effects”.4 They introduce 1-testosterone as “one of the most frequently misused steroids, often declared to be a prohormone,” and note that “the use of steroid precursors (prohormones) is illegal in the United States” since the start of 2005.4 The measured outcomes named in the summary are androgen receptor binding, transactivation of androgen-dependent reporter genes, growth of the prostate, seminal vesicles and levator ani muscle, and liver weight.4 The published summary names no species, doses, group sizes or duration for the in vivo work, so those details are not reported here.4 Their conclusion is that “1-Testo can be characterised as a typical anabolic steroid,” and they write that “It has to be assumed that consumption of this substance is associated with adverse side effects typical for this class of compounds”.4 The second statement is worded as an assumption, and the summary reports no adverse effects in people.4 The summary does not state the study’s funding, any competing interests or the authors’ own limitations.4
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~6 days
- Bioavailability
- 95%
- Typical dose
- 200–400 mg/week
- Route
- IM
- Time to peak
- ~36 h
Sources in this part
None of the papers or documents read reports a half-life, bioavailability, time to peak or concentration curve for 1-testosterone or its esters in people.
| Parameter | App’s figure | Reported in the sources read |
|---|---|---|
| Half-life | ~6 days (144 hours) | Not reported for 1-testosterone. In two horses given 800 mg by stomach tube, the parent drug was detected in urine for up to 30 h, which is a detection time, not a half-life.5 |
| Bioavailability (intramuscular) | 95% | Not reported. |
| Time to peak | ~36 h | Not reported. |
| Route | IM | The studies read gave 1-testosterone by stomach tube (horses) and a 1-androsterone capsule by mouth (one volunteer).5,6 |
Verheyden and colleagues at Ghent University (Analytica Chimica Acta, 2007) state that “1-Androstene-3beta,17beta-diol is transformed into 1-testosterone after oral administration”.7 The summary names no species, dose or time course for that statement.7
Deeper analysis: Kwok and colleagues, 2013 (horses)
Kwok and colleagues at the Racing Laboratory of The Hong Kong Jockey Club (Drug Testing and Analysis, 2013) studied the in vitro and in vivo metabolism of 1-testosterone in horses, “with the aim of identifying the most appropriate target metabolites to be monitored for controlling the misuse or abuse of 1-testosterone in racehorses”.5 Six in vitro metabolites were identified.5 For the in vivo part, “two thoroughbred geldings were each administered orally with 800 mg of 1-testosterone by stomach tubing”.5 “The parent drug and eight metabolites were detected in urine,” and the authors conclude that detection “is best achieved by monitoring the parent drug, which could be detected for up to 30 h post-administration”.5 In the opening sentences of the summary the authors write that “Metabolic studies on 1-testosterone have only been reported for human in the early seventies,” and that 1-testosterone “has an anabolic potency of 200 as compared to 26 for testosterone,” a figure the summary gives without a method or reference.5 The in vivo arm is two animals given one oral dose, and the summary states no funding, competing interests or limitations and does not say which human studies it refers to.5
Products and samples analysed
Sources in this part
Verheyden and colleagues describe 1-testosterone as “one of these substances presented to body-builders as a nutritional supplement or a pro-hormone”.7 Griffin, Lorenz and Flurer, at the US Food and Drug Administration’s Forensic Chemistry Center (Drug Testing and Analysis, 2022), reported that screening of an injectable liquid marketed for body building turned up “a steroid resembling 1-testosterone”.8 They identified it as 17β-hydroxy 5α-androst-1-en-3-one cypionate, “an analog of 1-testosterone that had not been reported”.8 The summary names the methods used (HPLC-UV with fraction collection, HRAM-MS, NMR spectrometry and GC-MS) and does not report a strength, purity or pharmacokinetics for the liquid.8 Aqai and colleagues at RIKILT in Wageningen (Analytical Chemistry, 2013) screened dietary supplements for designer steroids and reported that “1-testosterone was identified in three of the supplements studied”.9
Parr and colleagues (Steroids, 2011) analysed a product seized by the State Bureau of Criminal Investigation Schleswig-Holstein, Germany, named “1-Androsterone” and “labeled to contain 100mg of “1-Androstene-3b-ol,17-one” per capsule”.6 That product is a different substance from 1-testosterone, which appears in that paper as a urinary metabolite.6
Human studies
None of the papers read gave 1-testosterone to people and reported its blood levels or effects. Several papers involve people in other ways: a single volunteer who took a related supplement,6 a cross-sectional imaging study of bodybuilders,2 a case report on methyl-1-testosterone and ciclosporin,10 urine methods tested on human samples,3,12 and urine work on methyl-1-testosterone in people.13 Kwok and colleagues state that metabolic studies of 1-testosterone in humans were reported in the early 1970s; that work was not among the sources read.5
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Parr and colleagues, 20116 | Oral administration of a capsule product named “1-Androsterone”; urine monitored; the summary describes no comparator. | 1 male volunteer | The summary gives no separate dose and mentions “a single administration of one capsule” only for the nine-day detection finding; the product was labelled to contain 100 mg of “1-Androstene-3b-ol,17-one” per capsule. | 1-testosterone was one of the urinary metabolites detected; the urinary steroid profile ratios and the 5α-dihydrotestosterone concentration changed; a characteristic metabolite was detectable in screening up to nine days after one capsule. |
| Fuchs and colleagues, 20262 | Cross-sectional MRI and DXA study of three groups; drug use self-reported. | 15 recreationally active males, 15 competitive natural bodybuilders, 15 competitive bodybuilders using appearance- and performance-enhancing drugs (APED) | Self-reported use, averaging 6 ± 3 years; testosterone esters used by 93.3%, at an average 435 ± 257 mg/wk (n = 14); total weekly androgen dosage (n = 15) averaged 1019 ± 760 mg (range 58–2100 mg/wk); the drug-use table counts 3 of 15 under one row that lists boldenone undecylenate and dihydroboldenone (1-testosterone). | All visceral organ volumes were greater in the APED-using group than in natural bodybuilders and controls (P < 0.05), with no differences between those two groups (P > 0.05); liver volume averaged 2.57 ± 0.39, 1.82 ± 0.20 and 1.79 ± 0.21 L in the APED-using, natural bodybuilder and control groups. |
| Al-Niaimi and Lyon, 201310 | Case report of acute kidney injury; the compound was methyl-1-testosterone, a different compound from 1-testosterone. | 1 patient with severe atopic dermatitis | Dose and length not stated in the summary. | Acute kidney injury attributed to the interaction of ciclosporin with methyl-1-testosterone. |
Deeper analysis: Parr and colleagues, 2011 (1-androsterone supplement)
Parr and colleagues at the German Sport University Cologne analysed a seized “1-Androsterone” product and identified its steroid as 3β-hydroxy-5α-androst-1-en-17-one.6 After oral administration to a male volunteer, “1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one), 1-androstenedione (5α-androst-1-ene-3,17-dione), 3α-hydroxy-5α-androst-1-en-17-one, 5α-androst-1-ene-3α,17β-diol, and 5α-androst-1-ene-3β,17β-diol were detected besides the parent compound and two more metabolites”.6 The authors report that “common steroids of the urinary steroid profile were altered,” especially the ratios of androsterone/etiocholanolone and 5α-/5β-androstane-3α,17β-diol and the concentration of 5α-dihydrotestosterone.6 The volunteer took 1-androsterone, not 1-testosterone, so the paper shows that 1-testosterone can arise as a metabolite of that product and says nothing about the effects of taking 1-testosterone itself.6 The summary describes one volunteer, describes no comparator and states no funding, competing interests or limitations.6
Deeper analysis: Fuchs and colleagues, 2026 (bodybuilders)
Fuchs and colleagues at Maastricht University Medical Centre+ (Medicine and Science in Sports and Exercise, 2026) compared visceral organ volumes in bodybuilders who used appearance- and performance-enhancing drugs, natural bodybuilders and recreationally active controls.2 They report that “Bodybuilders using APED show substantially greater lean mass, muscle mass, as well as greater visceral organ volumes, compared with natural bodybuilders or age-matched controls”.2 Dihydroboldenone (1-testosterone) appears in a drug-use table row for “testosterone derivatives” that also lists boldenone undecylenate and covers 3 of the 15 users (20.0%).2 The authors state that “the APED-using bodybuilders reported using a heterogeneous mix of substances, doses, and administration routes, preventing determination of which specific agents may have contributed to the enlarged organ volumes,” and that “the cross-sectional design precludes conclusions about causality”.2 The study results therefore cannot be attributed to 1-testosterone.2 The authors also list water retention as a limitation: “APED use may cause water retention, meaning estimates of lean body, muscle, and visceral organ mass may partially reflect an increase in body water as part of an increase in tissue mass”.2 They add that “blood samples were not collected to assess androgen hormone concentrations or other pharmacological substances,” so the drug use in the table rests on self-report.2 The authors nonetheless conclude that “visceromegaly in bodybuilders cannot be attributed to a high-protein intake but is secondary to the use of APED,” a conclusion about the drugs as a group, which the study cannot assign to 1-testosterone.2 Two authors list AMRA Medical AB, Linköping, as their affiliation, and its software was used for muscle segmentation; the authors declare that “they have no conflicts of interest regarding this work and the publication of this article”.2 Funding came from the Stimuleringsfonds FHML, Maastricht, which the authors say “did not influence the study design, data analysis, or interpretation of results”.2
Doses reported in studies
The app lists a typical dose of 200 to 400 mg per week by intramuscular injection, and none of the papers read reports that dose or any dose of 1-testosterone or its esters given to people.
| Source | Subjects | Dose and route | Note |
|---|---|---|---|
| Kwok and colleagues, 20135 | 2 thoroughbred geldings | 800 mg of 1-testosterone, single oral dose by stomach tube | Metabolism study in horses; parent drug detected in urine for up to 30 h. |
| Parr and colleagues, 20116 | 1 male volunteer | No separate dose given; the product was labelled 100 mg of “1-Androstene-3b-ol,17-one” per capsule, taken by mouth | The substance taken was 1-androsterone, not 1-testosterone. |
| Fuchs and colleagues, 20262 | 15 bodybuilders using appearance- and performance-enhancing drugs | Total weekly androgen dosage averaged 1019 ± 760 mg (range 58–2100 mg/wk), self-reported; testosterone esters averaged 435 ± 257 mg/wk (n = 14) | All androgens combined; 1-testosterone not reported separately. |
Sources in this part
Side effects reported
Sources in this part
In the Friedel study, administration of 1-testosterone, unlike testosterone propionate, “results in a significant increase of liver weight” in vivo.4 The authors write that “It has to be assumed that consumption of this substance is associated with adverse side effects typical for this class of compounds”.4 In the Fuchs study, visceral organ volumes were greater in the group using appearance- and performance-enhancing drugs, and the authors state that the data cannot show which agents contributed.2 A search of PubMed on 16 November 2026 for 1-testosterone with hepatotoxicity, adverse effects or case report terms returned 19 records, and none of their titles reports an adverse event in a person given 1-testosterone. A separate 2013 case report by Al-Niaimi and Lyon (Dermatology and Therapy) describes acute kidney injury “due to the interaction of ciclosporin with methyl-1-testosterone,” which is a different compound from 1-testosterone.10
Bloodwork and markers
Sources in this part
The app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as markers for this compound, and none of the papers read reports any of them measured after 1-testosterone. In the one volunteer who took the 1-androsterone product, Parr and colleagues measured urinary steroids and reported changes in the androsterone/etiocholanolone ratio, the 5α-/5β-androstane-3α,17β-diol ratio and the 5α-dihydrotestosterone concentration.6
Regulatory and anti-doping status
Sources in this part
The WADA 2026 Prohibited List names 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one) among the anabolic androgenic steroids in section S1.1, which applies when administered exogenously.11 Section S1 is headed “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION),” and the list states that “All prohibited substances in this class are non-Specified Substances”.11 The list is issued as an International Standard under the World Anti-Doping Code, and it defines the In-Competition period by reference to a “Competition in which the Athlete is scheduled to participate”.11
| List or body | Entry | What it says |
|---|---|---|
| WADA Prohibited List 202611 | S1.1 anabolic androgenic steroids | Names 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one); prohibited at all times, in and out of competition. |
| US federal regulations, 21 CFR 1308.13(f)1 | Schedule III anabolic steroids, item (24) | Δ1-dihydrotestosterone (a.k.a. “1-testosterone”) (17β-hydroxy-5α-androst-1-en-3-one). |
| DailyMed drug labels | Search for the single term dihydroboldenone on 16 November 2026 | 0 labels returned. |
| ClinicalTrials.gov | Search for the single term dihydroboldenone on 16 November 2026 | 0 studies returned. |
The US schedule’s anabolic steroids paragraph applies “Unless specifically excepted or unless listed in another schedule,” and covers “any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers”.1 Piper and Thevis (Drug Testing and Analysis, 2022) note that “In 2020, the confirmation of the non-endogenous origin of several pseudo-endogenous steroids by means of isotope ratio mass spectrometry (IRMS) was recommended by the World Anti-Doping Agency (WADA),” and their method covers 17β-hydroxy-5α-androst-1-en-3-one.12 Controlled-substance status in countries other than the United States is not covered here.
What is not known
Sources in this part
- A half-life, bioavailability and time to peak for 1-testosterone in people: the papers read report none, and the app’s figures of about 6 days, 95% and about 36 h are not tied to a source.
- Any dose or schedule given to people, since the app’s range of 200 to 400 mg per week is not reported in the papers read.
- Whether the compound is aromatized, since the app’s statement that it is not has no test reported in the papers read.
- Effects on testosterone, estradiol, hematocrit, lipids or PSA in people, which the app lists as markers.
- The strength, purity and kinetics of the injectable liquid in which the FDA laboratory identified the cypionate analog, since its summary gives none of these.8
- What the early 1970s human metabolic studies of 1-testosterone, which Kwok and colleagues mention, reported: the papers read give no reference or result for them.5
- Whether findings for methyl-1-testosterone apply to 1-testosterone: Parr and colleagues (Endocrinology, 2011) identified methyl-1-testosterone as 17β-hydroxy-17α-methyl-5α-androst-1-en-3-one, a separate compound, and their results are not results for 1-testosterone.13
Frequently asked questions
What is DHB (1-testosterone)?
DHB is the abbreviation the app uses for dihydroboldenone, also called 1-testosterone, a steroid named 17β-hydroxy-5α-androst-1-en-3-one in US federal regulations.1 Friedel and colleagues reported that it binds the androgen receptor and that, in animals (the summary names no species), an equimolar dose matched testosterone propionate for growth of the prostate, seminal vesicles and levator ani muscle, while liver weight rose, unlike with testosterone propionate.4 These are tissue-weight findings, not effects in people.4
What is the half-life of DHB?
The app lists a half-life of about 6 days (144 hours) for DHB, and none of the papers or documents read measured a half-life of 1-testosterone in people. In two horses given 800 mg by stomach tube, Kwok and colleagues detected the parent drug in urine for up to 30 h, which is a detection time and not a half-life.5
Is DHB banned by WADA?
The WADA 2026 Prohibited List names 1-testosterone among the anabolic androgenic steroids in section S1.1, which applies when administered exogenously.11 The list is an International Standard under the World Anti-Doping Code, and it ties the In-Competition period to a “Competition in which the Athlete is scheduled to participate”.11 Section S1 is headed “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION),” and the list states that all prohibited substances in that class are non-Specified Substances.11
Is DHB a controlled substance in the US?
21 CFR 1308.13(f), the Schedule III paragraph on anabolic steroids, applies “Unless specifically excepted or unless listed in another schedule,” and lists “Δ1-dihydrotestosterone (a.k.a. “1-testosterone”) (17β-hydroxy-5α-androst-1-en-3-one)” as item (24).1 Other countries’ schedules are not covered here.
Does DHB aromatize?
The app’s notes state that DHB does not undergo aromatization. A search of PubMed on 16 November 2026 for 1-testosterone with aromatase or aromatization terms returned 5 records, and none of their titles concerns aromatization of 1-testosterone.
Has DHB been studied in humans?
None of the papers read gave 1-testosterone to people and reported its blood levels or effects, although Kwok and colleagues state that metabolic studies of 1-testosterone in humans were reported in the early 1970s and that work was not among the sources read.5 In one volunteer given a 1-androsterone product, 1-testosterone was among the urinary metabolites detected, and a 2026 imaging study of bodybuilders lists dihydroboldenone (1-testosterone) among self-reported drugs without separating its effects.6,2 A 2013 case report involved methyl-1-testosterone, a different compound.10
What is 17β-hydroxy 5α-androst-1-en-3-one cypionate?
17β-hydroxy 5α-androst-1-en-3-one cypionate is the compound that the US Food and Drug Administration’s Forensic Chemistry Center identified in an injectable liquid marketed for body building, and described it as “an analog of 1-testosterone that had not been reported”.8 The summary gives no strength, purity or pharmacokinetics for it and does not say that the liquid was sold as DHB.8
What are the side effects of DHB?
None of the papers read reports side effects of 1-testosterone in people. Friedel and colleagues reported a significant increase of liver weight with 1-testosterone, unlike testosterone propionate, in vivo, and wrote that “It has to be assumed that consumption of this substance is associated with adverse side effects typical for this class of compounds”.4
More in Other steroids
References
- U.S. Drug Enforcement Administration. 21 CFR 1308.13 Schedule III, paragraph (f) Anabolic steroids. Electronic Code of Federal Regulations, version of 1 November 2026. eCFR
- Fuchs CJ, et al. When Size Goes Inside: Visceromegaly in Bodybuilders Is Not Attributed to High-Protein Intake but More Likely Associated with the Use of Appearance- and Performance-Enhancing Drugs. Med Sci Sports Exerc 2026. PMC13446919
- Choi MH, et al. Determination of anabolic steroids by gas chromatography/negative-ion chemical ionization mass spectrometry and GC/NCI tandem mass spectrometry with heptafluorobutyric anhydride derivatization. Rapid Commun Mass Spectrom 1999. PMID 10209875
- Friedel A, et al. 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol Lett 2006. PMID 16621347
- Kwok WH, et al. Metabolic studies of 1-testosterone in horses. Drug Test Anal 2013. PMID 22715048
- Parr MK, et al. Seized designer supplement named "1-Androsterone": identification as 3β-hydroxy-5α-androst-1-en-17-one and its urinary elimination. Steroids 2011. PMID 21310167
- Verheyden K, et al. Mass spectrometric detection of and similarities between 1-androgens. Anal Chim Acta 2007. PMID 17386697
- Griffin KM, Lorenz LM, Flurer RA. Identification of the designer steroid 17β-hydroxy 5α-androst-1-en-3-one cypionate in an injectable liquid. Drug Test Anal 2022. PMID 34791803
- Aqai P, et al. High-throughput bioaffinity mass spectrometry for screening and identification of designer anabolic steroids in dietary supplements. Anal Chem 2013. PMID 23419079
- Al-Niaimi F, Lyon CC. Acute Kidney Injury Due to Interaction of Methyl-1-testosterone with Ciclosporin Metabolism in a Patient with Severe Atopic Dermatitis. Dermatol Ther (Heidelb) 2013. PMID 24281763
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force 1 January 2026. WADA 2026 list
- Piper T, Thevis M. Addressing recent challenges in isotope ratio mass spectrometry: development of a method applicable to 1-androstene-steroids, 6α-hydroxy-androstenedione, and androstatrienedione. Drug Test Anal 2022. PMID 36001066
- Parr MK, et al. Endocrine characterization of the designer steroid methyl-1-testosterone: investigations on tissue-specific anabolic-androgenic potency, side effects, and metabolism. Endocrinology 2011. PMID 21990312